Click here to view online. Add this email to your safelist.
US FDA grants Fasenra Orphan Drug Designation for hypereosinophilic syndrome
6 February 2019
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome (HES).
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
